The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats

Response by Lee et al to Letter Regarding Article, “Cardiovascular Risk of Isolated Systolic or Diastolic Hypertension in Young Adults”

(2021) Hokyou Lee et al.   CIRCULATION

Pathological cardiac remodeling seen by the eyes of proteomics

(2021) Diana Paola Gómez-Mendoza et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction

(2020) Kim A. Connelly et al.   Cardiovascular Diabetology

Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors

(2020) Thomas A. Zelniker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction

(2020) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure

(2020) Carlos G. Santos-Gallego et al.   JACC-Cardiovascular Imaging

Ischemic heart failure as a complication of incident acute myocardial infarction: Timing and time trends: A national analysis including 78,814 Danish patients during 2000–2009

(2019) Gerhard Sulo et al.   SCANDINAVIAN JOURNAL OF PUBLIC HEALTH

Metabolism of the failing heart and the impact of SGLT2 inhibitors

(2019) Alvaro Garcia-Ropero et al.   Expert Opinion on Drug Metabolism & Toxicology

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

(2019) Hsiang-Chun Lee et al.   Cardiovascular Diabetology

Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction

(2019) Salva R. Yurista et al.   EUROPEAN JOURNAL OF HEART FAILURE

Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics

(2019) Carlos G. Santos-Gallego et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

(2019) Milton Packer et al.   EUROPEAN JOURNAL OF HEART FAILURE

Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac myofibroblasts: Novel translational clues to EMPA-REG OUTCOME

(2019) Sean Kang et al.   CANADIAN JOURNAL OF CARDIOLOGY

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus

(2019) Jung-Chi Hsu et al.   Scientific Reports

Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation

(2018) Yumei Ye et al.   CARDIOVASCULAR DRUGS AND THERAPY

Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts

(2017) Tsung-Ming Lee et al.   FREE RADICAL BIOLOGY AND MEDICINE

High-Intensity Training Improves Global and Segmental Strains in Severe Congestive Heart Failure

(2017) Yair Blumberg et al.   JOURNAL OF CARDIAC FAILURE

Fibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis

(2017) Hadi Khalil et al.   JOURNAL OF CLINICAL INVESTIGATION

Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus

(2017) Leyna Leite Santos et al.   Revista da Associacao Medica Brasileira

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure

(2017) Milton Packer et al.   JAMA Cardiology

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

(2016) Antonius Baartscheer et al.   DIABETOLOGIA

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myofibroblasts in the Infarct Area: Concepts and Challenges

(2012) Evangelos P. Daskalopoulos et al.   MICROSCOPY AND MICROANALYSIS

Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities

(2010) Jason J. Gajarsa et al.   HEART FAILURE REVIEWS